Precision Oncology Startup Secures Fresh Funding For Global Expansion
Bengaluru-based precision oncology startup 4baseCare has raised a total of ₹128 crore ($13.3 million), including a fresh top-up round of ₹38 crore led by growX Ventures and Infosys, with participation from existing investors.
The latest investment comes just months after the company completed the first close of its Series B round, raising ₹90 crore from investors including Ashish Kacholia, Lashit Sanghvi, and Yali Capital.
The funding will help the company accelerate its global expansion plans while strengthening its genomics and artificial intelligence driven cancer care solutions.
Capital To Strengthen Genomics And AI Capabilities
According to the company, the newly raised capital will be deployed to expand its genomics laboratory network across international markets and enhance its AI-powered oncology platform.
4baseCare aims to improve access to precision cancer treatment for underrepresented populations across India, the Middle East, Southeast Asia, Latin America, and other emerging healthcare markets.
The startup believes that combining genomics, artificial intelligence, and real-world clinical data can significantly improve cancer diagnosis and treatment outcomes.
What Does 4baseCare Do?
Founded in 2019 by Hitesh Goswami and Kshitij Rishi, 4baseCare focuses on genomics-based cancer diagnostics and precision oncology solutions.
The company develops advanced genetic testing platforms that help oncologists identify personalized treatment pathways based on a patient’s genomic profile.
Its flagship platform, OncoTwin, uses clinico-genomic data and real-world patient information to generate AI-powered treatment insights for cancer specialists.
The platform is designed to support evidence-based treatment decisions and improve patient outcomes through personalized medicine.
Expanding Global Presence
4baseCare currently operates genomics laboratories across India, Dubai, Nepal, and the Philippines.
Following the latest funding round, the company plans to expand into 8 to 10 additional countries over the next 12 to 18 months.
The startup is also scaling its in-hospital genomics laboratory model through partnerships with leading healthcare institutions, including AIIMS Jammu, Max Healthcare, and Shankara Hospital.
These collaborations aim to make advanced cancer diagnostics more accessible directly within hospital ecosystems.
Genomic Testing Volumes Expected To Rise Significantly
The company currently performs approximately 1,500 genomic tests every month.
With ongoing expansion and new partnerships, 4baseCare expects testing volumes to increase significantly, targeting between 8,000 and 10,000 genomic tests per month in the coming years.
The growth reflects increasing adoption of precision medicine approaches, where treatment decisions are guided by an individual’s genetic and molecular profile.
As cancer care increasingly shifts toward personalized therapies, demand for genomic diagnostics is expected to rise across both developed and emerging markets.
Investor Interest In Oncology Startups Continues To Grow
The latest funding round highlights growing investor confidence in oncology-focused healthcare startups.
Cancer care and precision medicine have emerged as key areas of innovation within the healthcare ecosystem, attracting significant venture capital interest over the past few years.
Several startups in the oncology space have recently secured funding, including Everhope Oncology, which raised $10 million in seed capital, and MOC Cancer Care & Research Centre, which secured $18 million led by Elevation Capital.
Other notable players in the sector include ErlySign, OnCare, and OneCell Diagnostics.
With the latest capital infusion, 4baseCare aims to strengthen its position as a leading precision oncology platform serving emerging markets globally.
